Gene therapy for leukodystrophies

Human Molecular Genetics

Volumn 20, Issue , 2011, Pages

  Biffi, Alessandra ^a   Aubourg, Patrick ^b   Cartier, Nathalie ^b  

^a SAN RAFFAELE SCIENTIFIC INSTITUTE   (Italy)

^b INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ENHANCED GREEN FLUORESCENT PROTEIN; GALACTOSYLCERAMIDASE; GALACTOSYLCERAMIDE; GENE THERAPY AGENT; GLUTAMATE DECARBOXYLASE; GLUTAMIC ACID; LENTIVIRUS VECTOR; LYSOSOME ENZYME; NERVE GROWTH FACTOR; NEURTURIN; PARVOVIRUS VECTOR; PEPTIDASE; TRIPEPTIDYL PEPTIDASE I; UNCLASSIFIED DRUG;

ABCD1 GENE; ADRENOLEUKODYSTROPHY; ALZHEIMER DISEASE; ARTICLE; ASTROCYTE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BRAIN GENE THERAPY; CELL BASED GENE THERAPY; CNL2 GENE; DEMYELINATION; DISEASE COURSE; DOPAMINE METABOLISM; DRUG TOLERABILITY; EQUINE INFECTIOUS ANEMIA VIRUS; FOLLOW UP; GENE; GENE MUTATION; GENE TARGETING; GENOTOXICITY; GLOBOID CELL LEUKODYSTROPHY; GRAFT VERSUS HOST REACTION; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; LEUKEMOGENESIS; METACHROMATIC LEUKODYSTROPHY; MOLECULARLY TARGETED THERAPY; MUTAGENESIS; NERVOUS SYSTEM INFLAMMATION; NEUROPSYCHOLOGY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OLIGODENDROGLIA; PARKINSON DISEASE; PRIORITY JOURNAL; QUADRIPLEGIA; VIRAL GENE THERAPY;

ADRENOLEUKODYSTROPHY; GENE THERAPY; GENETIC VECTORS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HUMANS; LEUKODYSTROPHY, GLOBOID CELL; LEUKODYSTROPHY, METACHROMATIC; NEURODEGENERATIVE DISEASES;

EID: 79956007043     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddr142     Document Type: Article

References (103)

1. Mosser, J., Douar, A.M., Sarde, C.O., Kioschis, P., Feil, R., Moser, H., Poustka, A.M., Mandel, J-L. and Aubourg, P. (1993) Putative X-linked adrenoleukodystrophy gene shares unexpected homology with ABC transporters. Nature, 361, 726-730.
2. Moser, H.W., Mahmood, A. and Raymond, G.V. (2007) X-linked adrenoleukodystrophy. Nat. Clin. Pract. Neurol., 3, 140-151.
3. Polten, A., Fluharty, A.L., Fluharty, C.B., Kappler, J., von Figura, K. and Gieselmann, V. (1991) Molecular basis of different forms of metachromatic leukodystrophy. N. Engl. J. Med., 324, 18-22.
4. Von Figura, K., Gieselmann, V. and Jaeken, J. (2001) Metachromatic leukodystrophy. In Scriver, C., Beaudet, A., Sly, W. and Valle, D. (eds), The Metabolic and Molecular Bases of Inherited Disease. 8th ed. McGraw-Hill Published, New York, pp. 3695-3724.
5. Chen, Y.Q., Rafi, M.A., de Gala, G. and Wenger, D.A. (1993) Cloning and expression of cDNA encoding human galactocerebrosidase, the enzyme deficient in globoid cell leukodystrophy. Hum. Mol. Genet., 2, 1841-1845.
6. Wenger, D.A., Rafi, M.A., Luzi, P., Datto, J. and Costantino-Ceccarini, E. (2000) Krabbe disease: genetic aspects and progress toward therapy. Mol. Genet. Metab., 70, 1-9.
7. van der Knaap, M.S. and Valk, J. (2005) Classification of Myelin disorders in Magnetic Resonance of Myelination and Myelin Disorders. Spinger-Verlag. pp. 20-24.
8. Schiffmann, R. and van der Knaap, M.S. (2009) An MRI-based approach to the diagnosis of white matter disorders. Neurology, 72, 750-759.
9. Boespflug-Tanguy, O., Labauge, P., Fogli, A. and Vaurs-Barrier, C. (2008) Genes involved in leukodystrophies: a glance at glial functions. Curr. Neurol. Neurosci. Rep., 8, 217-222.
10. Kohlschütter, A., Bley, A., Brockmann, K., Gärtner, J., Krägeloh-Mann, I., Rolfs, A. and Schö ls, L. (2010) Leukodystrophies and other genetic metabolic leukoencephalopathies in children and adult. Brain Dev., 32, 82-89.
11. Brenner, M., Johnson, A.B., Boespflug-Tanguy, O., Rodriguez, D., Goldman, J.E. and Messing, A. (2001) Mutations in GFAP, encoding glial fibrillary acidic protein, are associated with Alexander disease. Nat. Genet., 27, 117-120.
12. Leegwater, P.A., Vermeulen, G., Könst, A.A., Naidu, S., Mulders, J., Visser, A., Kersbergen, P., Mobach, D., Fonds, D., van Berkel, C.G. et al. (2001) Subunits of the translation initiation factor eIF2B are mutant in leukoencephalopathy with vanishing white matter. Nat. Genet., 29, 383-388.
13. Schiffmann, R. and Elroy-Stein, O. (2006) Childhood ataxia with CNS hypomyelination/vanishing white matter disease-a common leukodystrophy caused by abnormal control of protein synthesis. Mol. Genet. Metab., 88, 7-15.
14. Kaul, R., Gao, G.P., Aloya, M., Balamurugan, K., Petrosky, A., Michals, K. and Matalon, R. (1994) Canavan disease: mutations among Jewish and non-Jewish patients. Am. J. Hum. Genet., 55, 34-41.
15. De Keyser, J., Mostert, J.P. and Koch, M.W. (2008) Dysfunctional astrocytes as key players in the pathogenesis of central nervous system disorders. J. Neurol. Sci., 267, 3-16.
16. Nave, K.A. and Trapp, B.D. (2008) Axon-glial signaling and the glial support of axon function. Annu. Rev. Neurosci., 31, 535-561.
17. Nave, K.A. (2010) Myelination and support of axonal integrity by glia. Nature, 468, 244-252.
18. Kornek, B., Storch, M.K., Weissert, R., Wallstroem, E., Stefferl, A., Olsson, T., Linington, C., Schmidbauer, M. and Lassmann, H. (2000) Multiple sclerosis and chronic autoimmune encephalomyelitis: a comparative quantitative study of axonal injury in active, inactive, and remyelinated lesions. Am. J. Pathol., 157, 267-276.
19. Griffiths, I., Klugmann, M., Anderson, T., Yool, D., Thomson, C., Schwab, M.H., Schneider, A., Zimmermann, F., McCulloch, M., Nadon, N. et al. (1998) Axonal swellings and degeneration in mice lacking the major proteolipid of myelin. Science, 280, 1610-1613.
20. Lappe-Siefke, C., Goebbels, S., Gravel, M., Nicksch, E., Lee, J., Braun, P.E., Griffiths, I.R. and Nave, K.A. (2003) Disruption of Cnp1 uncouples oligodendroglial functions in axonal support and myelination. Nat. Genet., 33, 366-374.
21. Garbern, J.Y., Yool, D.A., Moore, G.J., Wilds, I.B., Faulk, M.W., Klugmann, M., Nave, K.A., Sistermans, E.A., van der Knaap, M.S., Bird, T.D. et al. (2002) Patients lacking the major CNS myelin protein, proteolipid protein 1, develop length dependent axonal degeneration in the absence of demyelination and inflammation. Brain, 125, 551-561.
22. Franklin, R.J. and Ffrench-Constant, C. (2008) Remyelination in the CNS: from biology to therapy. Nat. Rev. Neurosci., 9, 839-855.
23. Foust, K.D., Nurre, E., Montgomery, C.L., Hernandez, A., Chan, C.M. and Kaspar, B.K. (2009) Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat. Biotechnol., 27, 59-65.
24. Koerber, J.T., Klimczak, R., Jang, J.H., Dalkara, D., Flannery, J.G. and Schaffer, D.V. (2009) Molecular evolution of adeno-associated virus for enhanced glial gene delivery. Mol. Ther., 17, 2088-2095.
25. Perry, V.H., Nicoll, J.A. and Holmes, C. (2010) Microglia in neurodegenerative disease. Nat. Rev. Neurol., 6, 193-201.
26. Ransohoff, R.M. and Cardona, A.E. (2010) The myeloid cells of the central nervous system parenchyma. Nature, 468, 253-262.
27. Ginhoux, F., Greter, M., Leboeuf, M., Nandi, S., See, P., Gokhan, S., Mehler, M.F., Conway, S.J., Ng, L.G., Stanley, E.R. et al. (2010) Fate mapping analysis reveals that adult microglia derive from primitive macrophages. Science, 330, 841-845.
28. Graeber, M.B. (2010) Changing face of microglia. Science, 330, 783-788.
29. Hickey, W.F. and Kimura, H. (1988) Perivascular microglial cells of the CNS are bone marrow-derived and present antigen in vivo. Science, 239, 290-292.
30. Hobbs, J.R., Hugh-Jones, K., Barrett, A.J., Byron, N., Chambers, D., Henry, K., James, D.C., Lucas, C.F., Rogers, T.R., Benson, P.F. et al. (1981) Reversal of clinical features of Hurler's disease and biochemical improvement after treatment by bone-marrow transplantation. Lancet, 2, 709-712.
31. Krivit, W., Shapiro, E., Kennedy, W., Lipton, M., Lockman, L., Smith, S., Summers, C.G., Wenger, D.A., Tsai, M.Y., Ramsay, N.K. et al. (1990) Effective treatment of late infantile metachromatic leukodystrophy by bone marrow transplantation. N. Engl. J. Med., 332, 28-32.
32. Krivit, W., Shapiro, E.G., Peters, C., Wagner, J.E., Cornu, G., Kurtzberg, J., Wenger, D.A., Kolodny, E.H., Vanier, M.T., Loes, D.J. et al. (1998) Hematopoietic stem-cell transplantation in globoid-cell leukodystrophy. N. Engl. J. Med., 338, 1119-1126.
33. Aubourg, P., Blanche, S., Jambaque, I., Rocchiccioli, F., Kalifa, G., Naud-Saudreau, C., Rolland, M.O., Debre, M., Chaussain, J.L., Griscelli, C. et al. (1990) Reversal of early neurologic and neuroradiologic manifestations of X-linked adrenoleukodystrophy by bone marrow transplantation. N. Engl. J. Med., 322, 1860-1866.
34. Priller, J., Flügel, A., Wehner, T., Boentert, M., Haas, C.A., Prinz, M., Fernández-Klett, F., Prass, K., Bechmann, I., de Boer, B.A. et al. (2001) Targeting gene-modified hematopoietic cells to the central nervous system: use of green fluorescent protein uncovers microglial engraftment. Nat. Med., 7, 1356-1361.
35. Mildner, A., Schmidt, H., Nitsche, M., Merkler, D., Hanisch, U.K., Mack, M., Heikenwalder, M., Brück, W., Priller, J. and Prinz, M. (2007) Microglia in the adult brain arise from Ly-6ChiCCR2+ monocytes only under defined host conditions. Nat. Neurosci., 10, 1544-1553.
36. Soulas, C., Donahue, R.E., Dunbar, C.E., Persons, D.A., Alvarez, X. and Williams, K.C. (2009) Genetically modified CD34+ hematopoietic stem cells contribute to turnover of brain perivascular macrophages in long-term repopulated primates. Am. J. Pathol., 174, 1808-1817.
37. Miyoshi, H., Smith, K.A., Mosier, D.E., Verma, I.M. and Torbett, B.E. (1999) Transduction of human CD34+ cells that mediate long-term engraftment of NOD/SCID mice by HIV vectors. Science, 283, 682-686.
38. Hwang, W.Y., Samuel, M., Tan, D., Koh, L.P., Lim, W. and Linn, Y.C. (2007) A meta-analysis of unrelated donor umbilical cord blood transplantation versus unrelated donor bone marrow transplantation in adult and pediatric patients. Biol. Blood Marrow Transplant., 13, 444-453.
39. Biffi, A., De Palma, M., Quattrini, A., Del Carro, U., Amadio, S., Visigalli, I., Sessa, M., Fasano, S., Brambilla, R., Marchesini, S. et al. (2004) Correction of metachromatic leukodystrophy in the mouse model by transplantation of genetically modified hematopoietic stem cells. J. Clin. Invest., 113, 1118-1129.
40. Biffi, A., Capotondo, A., Fasano, S., del Carro, U., Marchesini, S., Azuma, H., Malaguti, M.C., Amadio, S., Brambilla, R., Grompe, M. et al. (2006) Gene therapy of metachromatic leukodystrophy reverses neurological damage and deficits in mice. J. Clin. Invest., 116, 3070-3082.
41. Gentner, B., Visigalli, I., Hiramatsu, H., Lechman, E., Ungari, S., Giustacchini, A., Schira, G., Amendola, M., Quattrini, A., Martino, S. et al. (2010) Identification of hematopoietic stem cell-specific miRNAs enables gene therapy of globoid cell leukodystrophy. Sci. Transl. Med., 2, 58ra84.
42. Pujol, A., Hindelang, C., Callizot, N., Bartsch, U., Schachner, M. and Mandel, J. (2002) Late onset neurological phenotype of the X-ALD gene inactivation in mice: a mouse model for adrenomyeloneuropathy. Hum. Mol. Genet., 11, 499-505.
43. Fourcade, S., López-Erauskin, J., Galino, J., Duval, C., Naudi, A., Jov, M., Kemp, S., Villarroya, F., Ferrer, I., Pamplona, R. et al. (2008) Early oxidative damage underlying neurodegeneration in X-adrenoleukodystrophy. Hum. Mol. Genet., 17, 1762-1773.
44. Shapiro, E., Krivit, W., Lockman, L., Jambaqué, I., Peters, C., Cowan, M., Harris, R., Blanche, S., Bordigoni, P., Loes, D. et al. (2000) Long-term effect of bone-marrow transplantation for childhood-onset cerebral X-linked adrenoleukodystrophy. Lancet, 356, 713-718.
45. Peters, C., Charnas, L.R., Tan, Y., Ziegler, R.S., Shapiro, E.G., DeFor, T., Grewal, S.S., Orchard, P.J., Abel, S.L., Goldman, A.I. et al. (2004) Cerebral X-linked adrenoleukodystrophy: the international hematopoietic cell transplantation experience from 1982 to 1999. Blood, 104, 881-888.
46. Mahmood, A., Raymond, G.V., Dubey, P., Peters, C. and Moser, H.W. (2007) Survival analysis of haematopoietic cell transplantation for childhood cerebral X-linked adrenoleukodystrophy: a comparison study. Lancet Neurol., 6, 687-692.
47. Nowaczyk, M.J., Saunders, E.F., Tein, I., Blaser, S.I. and Clarke, J.T. (1997) Immunoablation does not delay the neurologic progression of X-linked adrenoleukodystrophy. J. Pediatr., 131, 453-455.
48. Eichler, F.S., Ren, J.Q., Cossoy, M., Rietsch, A.M., Nagpal, S., Moser, A.B., Frosch, M.P. and Ransohoff, R.M. (2008) Is microglial apoptosis an early pathogenic change in cerebral X-linked adrenoleukodystrophy? Ann. Neurol., 63, 729-742.
49. Benhamida, S., Pflumio, F., Dubart-Kupperschmitt, A., Zhao-Emonet, J.C., Cavazzana-Calvo, M., Rocchiccioli, F., Fichelson, S., Aubourg, P., Charneau, P. and Cartier, N. (2003) Transduced CD34+ cells from adrenoleukodystrophy patients with HIV-derived vector mediate long-term engraftment of NOD/SCID mice. Mol. Ther., 7, 317-324.
50. Cartier, N., Hacein-Bey-Abina, S., Bartholomae, C.C., Veres, G., Schmidt, M., Kutschera, I., Vidaud, M., Abel, U., Dal-Cortivo, L., Caccavelli, L. et al. (2009) Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science, 326, 818-823.
51. Asheuer, M., Pflumio, F., Benhamida, S., Dubart-Kupperschmitt, A., Fouquet, F., Imai, Y., Aubourg, P. and Cartier, N. (2004) Human CD34+ cells differentiate into microglia and express recombinant therapeutic protein. Proc. Natl Acad. Sci. USA, 101, 3557-3562.
52. Aubourg, P., Hematopoietic stem cell gene therapy with lentiviral vector in X-linked Adrenoleukodystrophy. XVIIIth Annual Congress of the European Society of Gene and Cell Therapy, 22-25 October 2010, Milano, Italy.
53. Hacein-Bey-Abina, S., Garrigue, A., Wang, G.P., Soulier, J., Lim, A., Morillon, E., Clappier, E., Caccavelli, L., Delabesse, E., Beldjord, K. et al. (2008) Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J. Clin. Invest., 118, 3132-3142.
54. De Palma, M., Montini, E., Santoni de Sio, F.R., Benedicenti, F., Gentile, A., Medico, E. and Naldini, L. (2005) Promoter trapping reveals significant differences in integration site selection between MLV and HIV vectors in primary hematopoietic cells. Blood, 105, 2307-2315.
55. Montini, E., Cesana, D., Schmidt, M., Sanvito, F., Ponzoni, M., Bartholomae, C., Sergi Sergi, L., Benedicenti, F., Ambrosi, A., Di Serio, C. et al. (2006) Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nat. Biotechnol., 24, 687-696.
56. Montini, E., Cesana, D., Schmidt, M., Sanvito, F., Bartholomae, C.C., Ranzani, M., Benedicenti, F., Sergi, L.S., Ambrosi, A., Ponzoni, M. et al. (2009) The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy. J. Clin. Invest., 119, 964-975.
57. Cavazzana-Calvo, M., Payen, E., Negre, O., Wang, G., Hehir, K., Fusil, F., Down, J., Denaro, M., Brady, T., Westerman, K. et al. (2010) Transfusion independence and HMGA2 activation after gene therapy of human b-thalassaemia. Nature, 467, 318-322.
58. Hess, B., Saftig, P., Hartmann, D., Coenen, R., Lullmann-Rauch, R., Goebel, H.H., Evers, M., von Figura, K., D'Hooge, R., Nagels, G. et al. (1996) Phenotype of arylsulfatase A-deficient mice: relationship to human metachromatic leukodystrophy. Proc. Natl Acad. Sci. USA, 93, 14821-14826.
59. Yaghootfam, A., Gieselmann, V. and Eckhardt, M. (2005) Delay of myelin formation in arylsulphatase A-deficient mice. Eur. J. Neurosci., 21, 711-720.
60. Eckhardt, M., Hedayati, K.K., Pitsch, J., Lüllmann-Rauch, R., Beck, H., Fewou, S.N. and Gieselmann, V. (2007) Sulfatide storage in neurons causes hyperexcitability and axonal degeneration in a mouse model of metachromatic leukodystrophy. J. Neurosci., 27, 9009-9021.
61. Ramakrishnan, H., Hedayati, K.K., Lüllmann-Rauch, R., Wessig, C., Fewou, S.N., Maier, H., Goebel, H.H., Gieselmann, V. and Eckhardt, M. (2007) Increasing sulfatide synthesis in myelin-forming cells of arylsulfatase A-deficient mice causes demyelination and neurological symptoms reminiscent of human metachromatic leukodystrophy. J. Neurosci., 27, 9482-9490.
62. Marcus, J. and Popko, B. (2002) Galactolipids are molecular determinants of myelin development and axo-glial organization. Biochim. Biophys. Acta, 1573, 406-413.
63. Suzuki, K. (1998) Twenty five years of the "psychosine hypothesis": a personal perspective of its history and present status. Neurochem. Res., 23, 251-259.
64. Zaka, M., Rafi, M.A., Rao, H.Z., Luzi, P. and Wenger, D. (2005) Insulin-like growth factor-1 provides protection against psycosine-onduced apoptosis in cultured mouse oligodendrocyte progenitor cells using primarily the P13K/Akt pathway. Mol. Cell Neurosci., 30, 398-407.
65. Giri, S., Khan, M., Rattan, R., Singh, I. and Singh, A.K. (2006) Krabbe disease: psychosine-mediated activation of phospholipase A2 in oligodendrocyte cell death. J. Lipid. Res., 47, 1478-1492.
66. Giri, S., Khan, M., Nath, N., Singh, I. and Singh, A.K. (2008) The role of AMPKin psychosine mediated effects on oligodendrocytes and astrocytes: implication for Krabbe disease. J. Neurochem., 105, 1820-1833.
67. Suzuki, K. (2003) Globoid cell leukodystrophy (Krabbe's disease): update. J. Child Neurol., 18, 595-603.
68. Kurtz, H.J. and Fletcher, T.F. (1970) The peripheral neuropathy of canine globoid-cell leukodystrophy (krabbe-type). Acta Neuropathol., 16, 226-232.
69. Kobayashi, T., Shinnoh, N., Goto, I. and Kuroiwa, Y. (1985) Hydrolysis of galactosylceramide is catalyzed by two genetically distinct acid beta-galactosidases. J. Biol. Chem., 260, 14982-14987.
70. Baskin, G.B., Ratterree, M., Davison, B.B., Falkenstein, K.P., Clarke, M.R., England, J.D., Vanier, M.T., Luzi, P., Rafi, M.A. and Wenger, D.A. (1998) Genetic galactocerebrosidase deficiency (globoid cell leukodystrophy, Krabbe disease) in rhesus monkeys (Macaca mulatta). Lab. Anim. Sci., 48, 476-482.
71. Luzi, P., Rafi, M.A., Zaka, M., Rao, H.Z., Curtis, M., Vanier, M.T. and Wenger, D.A. (2001) Generation of a mouse with low galactocerebrosidase activity by gene targeting: a new model of globoid cell leukodystrophy (Krabbe disease). Mol. Genet. Metab., 73, 211-223.
72. Brady, R.O. and Schiffmann, R. (2004) Enzyme-replacement therapy for metabolic storage disorders. Lancet Neurol., 3, 752-756.
73. Matzner, U., Lüllmann-Rauch, R., Stroobants, S., Andersson, C., Weigelt, C., Eistrup, C., Fogh, J., D'Hooge, R. and Gieselmann, V. (2009) Enzyme replacement improves ataxic gait and central nervous system histopathology in a mouse model of metachromatic leukodystrophy. Mol. Ther., 17, 600-606.
74. Escolar, M.L., Poe, M.D., Provenzale, J.M., Richards, K.C., Allison, J., Wood, S., Wenger, D.A., Pietryga, D., Wall, D., Champagne, M. et al. (2005) Transplantation of umbilical-cord blood in babies with infantile Krabbe's disease. N. Engl. J. Med., 352, 2069-2081.
75. Matzner, U., Hartmann, D., Lüllmann-Rauch, R., Coenen, R., Rothert, F., Månsson, J.E., Fredman, P., D'Hooge, R., De Deyn, P.P. and Gieselmann, V. (2002) Bone marrow stem cell-based gene transfer in a mouse model for metachromatic leukodystrophy: effects on visceral and nervous system disease manifestations. Gene Ther., 9, 53-63.
76. Sardiello, M., Annunziata, I., Roma, G. and Ballabio, A. (2005) Sulfatases and sulfatase modifying factors: an exclusive and promiscuous relationship. Hum. Mol. Genet., 14, 3203-3217.
77. Cosma, M.P., Pepe, S., Annunziata, I., Newbold, R.F., Grompe, M., Parenti, G. and Ballabio, A. (2003) The multiple sulfatase deficiency gene encodes an essential and limiting factor for the activity of sulfatases. Cell, 113, 445-456.
78. Dierks, T., Schmidt, B., Borissenko, L.V., Peng, J., Preusser, A., Mariappan, M. and von Figura, K. (2003) Multiple sulfatase deficiency is caused by mutations in the gene encoding the human C(alpha)-formylglycine generating enzyme. Cell, 113, 435-444.
79. Capotondo, A., Cesani, M., Pepe, S., Fasano, S., Gregori, S., Tononi, L., Venneri, M.A., Brambilla, R., Quattrini, A., Ballabio, A. et al. (2007) Safety of arylsulfatase A overexpression for gene therapy of metachromatic leukodystrophy. Hum. Gene Ther., 18, 821-836.
80. Visigalli, I., Ungari, S., Martino, S., Park, H., Cesani, M., Gentner, B., Sergi Sergi, L., Orlacchio, A., Naldini, L. and Biffi, A. (2010) The galactocerebrosidase enzyme contributes to the maintenance of a functional hematopoietic stem cell niche. Blood, 116, 1857-1866.
81. Brown, B.D., Venneri, M.A., Zingale, A., Sergi Sergi, L. and Naldini, L. (2006) Endogenous microRNA regulation suppresses transgene expression in hematopoietic lineages and enables stable gene transfer. Nat. Med., 12, 585-591.
82. Brown, B.D., Gentner, B., Cantore, A., Colleoni, S., Amendola, M., Zingale, A., Baccarini, A., Lazzari, G., Galli, C. and Naldini, L. (2007) Endogenous microRNA can be broadly exploited to regulate transgene expression according to tissue, lineage and differentiation state. Nat. Biotechnol., 25, 1457-1467.
83. Orchard, P.J. and Wagner, J.E. (2011) Leukodystrophy and gene therapy with a dimmer switch. N. Engl. J. Med., 364, 572-573.
84. Kaplitt, M.G., Feigin, A., Chengke, T., Fitzsimons, H.L., Mattis, P., Lawlor, P.A., Bland, R.J., Young, D., Strybing, K., Eidelberg, D. et al. (2007) Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial. Lancet, 369, 2097-2105.
85. Feigin, A., Kaplit, M.G., Tang, C., Lin, T., Mattis, P., Dhawan, V., During, M.J. and Eidelberg, D. (2007) Modulation of metabolic brain networks after subthalamic gene therapy for Parkinson's disease. Proc. Natl Acad. Sci. USA, 104, 19559-19564.
86. Kordower, J.H., Herzog, C.D., Dass, B., Bakay, R.A.E., Stansell, J. III, Gasmi, M. and Bartus, R.T. (2006) Delivery of neurturin by AAV2 (CERE-120)-mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP-treated monkeys. Ann. Neurol., 60, 706-715.
87. Marks, W.J. Jr, Bartus, R.T., Siffert, J., Davis, C.S., Lozano, A., Boulis, N., Vitek, J., Stacy, M., Turner, D., Verhagen, L. et al. (2010) Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol., 9, 1164-1172.
88. Christine, C.W., Starr, P.A., Larson, P.S., Eberling, J.L., Jagust, W.J., Hawkins, R.A., VanBrocklin, H.F., Wright, J.F., Bankiewicz, K.S., Aminoff, M.J. et al. (2009) Safety and tolerability of putaminal AADC gene therapy for Parkinson disease. Neurology, 73, 1662-1669.
89. Jarraya, B., Boulet, S., Ralph, G.S., Jan, C., Bonvento, G., Azzouz, M., Miskin, J.E., Shin, M., Delzescaux, T., Drouot, X. et al. (2009) Dopamine gene therapy for Parkinson's disease in a nonhuman primate without associated dyskinesia. Sci. Transl. Med., 1, 2ra4
90. Tuszynski, M.H., Thal, L., Pay, M., Salmon, D.P., U, H.S., Bakay, R., Patel, P., Blesch, A., Vahlsing, H.L., Ho, G. et al. (2005) A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat. Med., 11, 551-555.
91. Worgall, S., Sondhi, D., Hackett, N.R., Kosofsky, B., Kekatpure, M.V., Neyzi, N., Dyke, J.P., Ballon, D., Heier, L., Greenwald, B.M. et al. (2008) Treatment of late infantile neuronal ceroid lipofuscinosis by CNS administration of a serotype 2 adeno-associated virus expressing CLN2 cDNA. Hum. Gene Ther., 19, 463-467.
92. Wang, Z., Ma, H.I., Li, J., Sun, L., Zhang, J. and Xiao, X. (2003) Rapid and highly efficient transduction by double-stranded adeno-associated virus vectors in vitro and in vivo. Gene Ther., 10, 2105-2111.
93. Cearley, C.N. and Wolfe, J.H. (2007) A single injection of an adeno-associated virus vector into nuclei with divergent connections results in widespread vector distribution in the brain and global correction of a neurogenetic disease. J. Neurosci., 27, 9928-9940.
94. Souweidane, M.M., Fraser, J.F., Arkin, L.M., Sondhi, D., Hackett, N.R., Kaminsky, S.M., Heier, L., Kosofsky, B.E., Worgall, S., Crystal, R.G. and Kaplitt, M.G. (2010) Gene therapy for late infantile neuronal ceroid lipofuscinosis: neurosurgical considérations. J. Neurosurg. Pediatr., 6, 115-122.
95. Kells, A.P., Hadaczek, P., Yin, D., Bringas, J., Varenika, V., Forsayeth, J. and Bankiewicz, K.S. (2009) Efficient gene therapy-based method for the delivery of therapeutics to primate cortex. Proc. Natl Acad. Sci. USA, 106, 2407-2411.
96. Luca, T., Givogri, M.I., Perani, L., Galbiati, F., Follenzi, A., Naldini, L. and Bongarzone, E.R. (2005) Axons mediate the distribution of arylsulfatase A within the mouse hippocampus upon gene delivery. Mol. Ther., 12, 669-679.
97. Sevin, C., Benraiss, A., Van Dam, D., Bonnin, D., Nagels, G., Verot, L., Laurendeau, I., Vidaud, M., Gieselmann, V., Vanier, M.T., De Deyn, P.P. et al. (2006) Intracerebral adeno-associated virus-mediated gene transfer in rapidly progressive forms of metachromatic leukodystrophy. Hum. Mol. Genet., 15, 53-64.
98. Sevin, C., Verot, L., Benraiss, A., Van Dam, D., Bonnin, D., Nagels, G., Fouquet, F., Gieselmann, V., Vanier, M.T., De Deyn, P.P., Aubourg, P. et al. (2007) Partial cure of established disease in an animal model of metachromatic leukodystrophy after intracerebral adeno-associated virus-mediated gene transfer. Gene Ther., 14, 405-414.
99. Colle, M.A., Piguet, F., Bertrand, L., Raoul, S., Bieche, I., Dubreil, L., Sloothaak, D., Bouquet, C., Moullier, P., Aubourg, P., Cherel, Y. et al. (2010) Efficient intracerebral delivery of AAV5 vector encoding human ARSA in non-human primate. Hum. Mol. Genet., 19, 147-158.
100. Sondhi, D., Hackett, N.R., Peterson, D.A., Stratton, J., Baad, M., Travis, K.M., Wilson, J.M. and Crystal, R.G. (2007) Enhanced survival of the LINCL mouse following CLN2 gene transfer using the rh.10 rhesus macaque-derived adeno-associated virus vector. Mol. Ther., 15, 481-491.
101. Watson, G., Bastacky, J., Belichenko, P., Buddhikot, M., Jungles, S., Vellard, M., Mobley, W.C. and Kakkis, E. (2006) Intrathecal administration of AAV vectors for the treatment of lysosomal storage in the brains of MPS I mice. Gene Ther., 13, 917-925.
102. Vulchanova, L., Schuster, D.J., Belur, L.R., Riedl, M.S., Podetz-Pedersen, K.M., Kitto, K.F., Wilcox, G.L., McIvor, R.S. and Fairbanks, C.A. (2010) Differential adeno-associated virus mediated gene transfer to sensory neurons following intrathecal delivery by direct lumbar puncture. Mol. Pain, 6, 31.
103. Chen, Y.H., Chang, M. and Davidson, B.L. (2009) Molecular signature of disease brain endothelia provide new sites for CNS-directed enzyme therapy. Nat. Med., 15, 1215-1218.